Targeting the Microenvironment in MDS: The Final Frontier

Patric Teodorescu, Sergiu Pasca, Delia Dima, Ciprian Tomuleasa, Gabriel Ghiaur

Research output: Contribution to journalReview articlepeer-review


Myelodysplastic syndromes (MDS) are a heterogeneous group of malignant disorders of hematopoietic stem and progenitor cells (HSPC), mainly characterized by ineffective hematopoiesis leading to peripheral cytopenias and progressive bone marrow failure. While clonal dominance is nearly universal at diagnosis, most genetic mutations identified in patients with MDS do not provide a conspicuous advantage to the malignant cells. In this context, malignant cells alter their adjacent bone marrow microenvironment (BME) and rely on cell extrinsic factors to maintain clonal dominance. The profoundly disturbed BME favors the myelodysplastic cells and, most importantly is detrimental to normal hematopoietic cells. Thus, the MDS microenvironment not only contributes to the observed cytopenias seen in these patients but could also negatively impact the engraftment of normal, allogeneic HSPCs in patients with MDS undergoing bone marrow transplant. Therefore, successful therapies in MDS should not only target the malignant cells but also reprogram their bone marrow microenvironment. Here, we will provide a synopsis of how drugs currently used or on the verge of being approved for the treatment of MDS may achieve this goal.

Original languageEnglish (US)
Article number1044
JournalFrontiers in Pharmacology
StatePublished - Jul 9 2020


  • CYP26 enzymes
  • all-trans retinoic acid
  • azacytidine
  • lenalidomide
  • luspatercept
  • microenvironment
  • myelodyslastic syndromes
  • rigosertib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Targeting the Microenvironment in MDS: The Final Frontier'. Together they form a unique fingerprint.

Cite this